F9Y-18806-42091
2 vaccinations
5 coded responses
11 check-ins
5 free-text entries
3 call cases
- Sex
- Female
- Age at first dose
- 46-50
- ZIP prefix
- 207 / MD
- Registered
- 2021-01-02
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-15
Dose 1 — Pfizer-BioNTech
-
2021-01-02
Registered in v-safe
-
2021-01-02
Survey response — day 14, dose 1MedDRA: Eye discharge, Eye infection, Impetigo, Nasal crusting, Nasal discomfort — Feeling: GoodFree text: 1. Right eye injection and discharge x 12 hours2. Left focal nasal mucosal irritation/scab formation. Appears impetgo- like.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-06
- 2021-01-07
-
2021-01-12
Dose 2 — Pfizer-BioNTech
- 2021-01-26
-
2021-02-04
Survey response — day 21, dose 2MedDRA: Lymphadenopathy, Rash, Rash papular — Feeling: GoodFree text: 1. ~3cm enlarged anterior cervical lymph node, appeared 5-6 days after 2nd shot (1/12) and is still present. 2. 3 erythematous papules about 3-4mm in diameter, now present for ~7 days in hand and distal Arm. One on ventral hand surface.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-09
-
2021-02-16
Survey response — day 35, dose 2MedDRA: Vasculitic rash — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Vascular rash (awaiting biopsy results)MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-16
Report sent to call center — day 35, dose 2Get care from a doctor or other healthcare professional1 call case(s)
-
2021-02-23
Survey response — day 42, dose 2MedDRA: Vasculitic rash — Feeling: Fair · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: My vasculitic rash is worsening. Have a biopsy pending.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-23
Report sent to call center — day 42, dose 2Get care from a doctor or other healthcare professional1 call case(s)
-
2021-04-13
Survey response — 3 months, dose 2MedDRA: Idiopathic intracranial hypertension, Rheumatic disorder, Sarcoidosis — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: 1. Idiopathic intracranial hypertension2. Suspected new-onset rheum dz thought to be sarcoidosisMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-13
Report sent to call center — 3 months, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-06-15
Call successfulReported to VAERS voluntarily prior to GDIT contact
- 2021-07-15
- 2022-01-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-15 | Pfizer-BioNTech | |
| 2 | 2021-01-12 | Pfizer-BioNTech |
Call center
3 call center cases
3 successful
VAERS report filed, before or during a call: 3
Free text
Release 1 — day 14, dose 1
Symptoms: 1. Right eye injection and discharge x 12 hours2. Left focal nasal mucosal irritation/scab formation. Appears impetgo- like.
Release 3 — day 21, dose 2
Symptoms: 1. ~3cm enlarged anterior cervical lymph node, appeared 5-6 days after 2nd shot (1/12) and is still present. 2. 3 erythematous papules about 3-4mm in diameter, now present for ~7 days in hand and distal Arm. One on ventral hand surface.
Release 4 — day 35, dose 2
Symptoms: Vascular rash (awaiting biopsy results)
Release 4 — day 42, dose 2
Symptoms: My vasculitic rash is worsening. Have a biopsy pending.
Release 7 — 3 months, dose 2
Symptoms: 1. Idiopathic intracranial hypertension2. Suspected new-onset rheum dz thought to be sarcoidosis
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Eye discharge | ✓ | ✓ | ✓ |
| SD | Eye infection | ✓ | ✓ | ✓ |
| SD | Idiopathic intracranial hypertension | ✓ | ✓ | ✓ |
| SD | Impetigo | ✓ | ✓ | ✓ |
| SD | Lymphadenopathy | ✓ | ✓ | ✓ |
| SD | Nasal crusting | ✓ | ✓ | ✓ |
| SD | Nasal discomfort | ✓ | ✓ | ✓ |
| SD | Rash | ✓ | ✓ | ✓ |
| SD | Rash papular | ✓ | ✓ | ✓ |
| SD | Rheumatic disorder | ✓ | ✓ | ✓ |
| SD | Sarcoidosis | ✓ | ✓ | ✓ |
| SD | Vasculitic rash | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release